The effect of age and the H1c MAPT haplotype on MAPT expression in human brain, Neurobiology of Aging, vol.30, issue.10 ,
DOI : 10.1016/j.neurobiolaging.2007.12.017
The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts, Neurobiology of Disease, vol.25, issue.3, pp.561-570, 2007. ,
DOI : 10.1016/j.nbd.2006.10.018
Haplotype-specific expression of exon 10 at the human MAPT locus, Human Molecular Genetics, vol.15, issue.24, pp.3529-3537, 2006. ,
DOI : 10.1093/hmg/ddl429
Brain tau expression and correlation with the H1/H1 tau genotype in frontotemporal lobar degeneration patients, Journal of Neural Transmission, vol.59, issue.12, pp.1585-1588, 2007. ,
DOI : 10.1007/s00702-007-0786-5
Tau and ??-synuclein in susceptibility to, and dementia in, Parkinson's disease, Annals of Neurology, vol.300, issue.2, pp.145-153, 2007. ,
DOI : 10.1002/ana.21192
Cerebral involvement in myotonic dystrophies, Muscle & Nerve, vol.9, issue.3, pp.294-306, 2007. ,
DOI : 10.1002/mus.20800
Cognitive impairment in adult myotonic dystrophies: a longitudinal study, Neurological Sciences, vol.28, issue.1, pp.9-15, 2007. ,
DOI : 10.1007/s10072-007-0742-z
RNA-mediated neuromuscular disorders . Annual review of neuroscience, pp.259-277, 2006. ,
DOI : 10.1146/annurev.neuro.29.051605.113014
Specific tau variants in the brains of patients with myotonic dystrophy, Neurology, vol.47, issue.3, pp.711-717, 1996. ,
DOI : 10.1212/WNL.47.3.711
Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy . Progress in molecular and subcellular biology, pp.133-159, 2006. ,
Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons, Human Molecular Genetics, vol.13, issue.24, pp.3079-3088, 2004. ,
DOI : 10.1093/hmg/ddh327
Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1, Human Molecular Genetics, vol.10, issue.19, pp.2143-2155, 2001. ,
DOI : 10.1093/hmg/10.19.2143
Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease, Neurology, vol.65, issue.10, pp.1636-1638, 2005. ,
DOI : 10.1212/01.wnl.0000184585.93864.4e
Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: Two individual consequences of CUG trinucleotide repeats, Experimental Neurology, vol.210, issue.2, pp.467-478, 2008. ,
DOI : 10.1016/j.expneurol.2007.11.020
URL : https://hal.archives-ouvertes.fr/hal-00282892
Myotonic dystrophy: Emerging mechanisms for DM1 and DM2, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1772, issue.2, pp.195-204, 2007. ,
DOI : 10.1016/j.bbadis.2006.05.013
URL : https://hal.archives-ouvertes.fr/hal-00562719
Stable-Tau Overexpression in Human Neuroblastoma Cells, Annals of the New York Academy of Sciences, vol.412, issue.1, pp.623-634, 2003. ,
DOI : 10.1196/annals.1299.115
Transgenic Mouse Model of Tauopathies with Glial Pathology and Nervous System Degeneration, Neuron, vol.35, issue.3, pp.433-446, 2002. ,
DOI : 10.1016/S0896-6273(02)00789-4
Increase in the relative expression of tau with four microtubule binding repeat regions in frontotemporal lobar degeneration and progressive supranuclear palsy brains, Acta Neuropathologica, vol.49, issue.5, pp.471-479, 2007. ,
DOI : 10.1007/s00401-007-0280-z
Three-repeat Tau 69 is a major tau isoform in laser-microdissected Pick bodies, Amyloid, vol.100, issue.1, pp.1-5, 2006. ,
DOI : 10.1016/0896-6273(92)90117-V
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study, Neurology, vol.71, issue.1, pp.28-34, 2008. ,
DOI : 10.1212/01.wnl.0000304051.01650.23
The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease, Journal of Neurochemistry, vol.280, issue.3, pp.635-644, 2006. ,
DOI : 10.1016/S0006-8993(99)01486-9
Different immunoreactivities of the microtubule-binding region of tau and its molecular basis in brains from patients with Alzheimer s disease, Pick s disease, progressive supranuclear palsy and corticobasal degeneration, Acta neuropathologica, vol.105, issue.5, pp.489-498, 2003. ,
Alterations in human tau transcripts correlate with those of neurofilament in sporadic tauopathies, Neuroscience Letters, vol.359, issue.3, pp.151-154, 2004. ,
DOI : 10.1016/j.neulet.2004.01.060
No alteration in tau exon 10 alternative splicing in tangle-bearing neurons of the Alzheimer???s disease brain, Acta Neuropathologica, vol.285, issue.4, pp.439-449, 2006. ,
DOI : 10.1007/s00401-006-0095-3
Tauopathies, Cellular and Molecular Life Sciences, vol.64, issue.17, pp.2219-2233, 2007. ,
DOI : 10.1007/s00018-007-7220-x
Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms, Journal of Neuroscience, vol.25, issue.22, pp.5446-5454, 2005. ,
DOI : 10.1523/JNEUROSCI.4637-04.2005
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function, Science, vol.309, issue.5733, pp.476-481, 2005. ,
DOI : 10.1126/science.1113694
Tau phosphorylation in Alzheimer s disease: pathogen or protector? ,
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death, Nature, vol.19, issue.7010, pp.805-810, 2004. ,
DOI : 10.1016/j.nbd.2004.04.001
Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles, Science, vol.293, issue.5530, pp.711-714, 2001. ,
DOI : 10.1126/science.1062382
Changed Conformation of Mutant Tau-P301L Underlies the Moribund Tauopathy, Absent in Progressive, Nonlethal Axonopathy of Tau-4R/2N Transgenic Mice, Journal of Biological Chemistry, vol.280, issue.5, pp.3963-3973, 2005. ,
DOI : 10.1074/jbc.M409876200
I PP2A 1 Affects Tau Phosphorylation via Association with the Catalytic Subunit of Protein Phosphatase 2A, Journal of Biological Chemistry, vol.283, issue.16, pp.10513-10521, 2008. ,
DOI : 10.1074/jbc.M709852200
Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer s disease ,
Sequential phosphorylation of tau protein by cAMP-dependent protein kinase and SAPK4/p38? or JNK2 in the presence of heparin generates the AT100 epitope, Journal of Neurochemistry, vol.61, issue.1, pp.154-164, 2006. ,
DOI : 10.1046/j.1432-1327.1998.2520542.x
Specific Pathological Tau Protein Variants Characterize Pick??s Disease, Journal of Neuropathology and Experimental Neurology, vol.55, issue.2, pp.159-168, 1996. ,
DOI : 10.1097/00005072-199602000-00004
Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment, Acta Neuropathologica, vol.92, issue.6, pp.588-596, 1996. ,
DOI : 10.1007/s004010050565
The Neuronal Microtubule-Associated Protein Tau Is a Substrate for Caspase-3 and an Effector of Apoptosis, Journal of Neurochemistry, vol.1, issue.2, pp.624-633, 2000. ,
DOI : 10.1046/j.1471-4159.2000.0750624.x
Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease, Proceedings of the National Academy of Sciences, vol.100, issue.17, pp.10032-10037, 2003. ,
DOI : 10.1073/pnas.1630428100
Calpain-Induced Proteolysis of Normal Human Tau and Tau Associated with Paired Helical Filaments, European Journal of Biochemistry, vol.15, issue.1, pp.9-17, 1995. ,
DOI : 10.1016/0014-5793(86)80060-6
Proteasomal degradation of tau protein, Journal of Neurochemistry, vol.72, issue.1, pp.176-185, 2002. ,
DOI : 10.1046/j.1471-4159.2002.01137.x
Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo, Journal of Neurochemistry, vol.69, issue.4, pp.1005-1014, 2006. ,
DOI : 10.1073/pnas.96.4.1391
Apoptotic effect of caspase-3 cleaved tau in hippocampal neurons and its potentiation by tau FTDP-mutation N279K, Journal of Alzheimer's Disease, vol.7, issue.1, pp.3-13, 2005. ,
DOI : 10.3233/JAD-2005-7102
Activation of caspase-6 in aging and mild cognitive impairment . The American journal of pathology, pp.1200-1209, 2007. ,
Proteasome inhibition and Tau proteolysis: an unexpected regulation, FEBS Letters, vol.69, issue.1, pp.1-5, 2005. ,
DOI : 10.1016/j.febslet.2004.11.018
The Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology, Journal of Neuropathology & Experimental Neurology, vol.64, issue.2, pp.104-112, 2005. ,
DOI : 10.1093/jnen/64.2.104
Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease, Journal of Alzheimer's Disease, vol.5, issue.2, pp.65-77, 2003. ,
DOI : 10.3233/JAD-2003-5201
Direct analysis of tau from PSP brain identifies new phosphorylation sites and a major fragment of N-terminally cleaved tau containing four microtubule-binding repeats, Journal of Neurochemistry, vol.60, issue.6, 2008. ,
DOI : 10.1111/j.1471-4159.2008.05321.x
Neurodegenerative Diseases, p.690, 2007. ,
DOI : 10.1007/978-1-59745-336-3_20
Molecular pathology of Alzheimer's disease in sporadic and familial Alzheimer's disease with mutations in the amyloid precursor protein, Biochemical Society Transactions, vol.20, issue.3, pp.642-645, 1992. ,
DOI : 10.1042/bst0200642
Different distribution of phosphorylated tau protein isoforms in Alzheimer's and Pick's diseases, FEBS Letters, vol.26, issue.3, pp.578-582, 1997. ,
DOI : 10.1016/S0014-5793(97)00859-4
Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms, Neuron, vol.8, issue.1, pp.159-168, 1992. ,
DOI : 10.1016/0896-6273(92)90117-V
Neurofibrillary Degeneration in Progressive Supranuclear Palsy andCorticobasal Degeneration. Tau Pathologies with Exclusively "Exon10" Isoforms, Journal of Neurochemistry, vol.72, issue.3, pp.1243-1249, 1999. ,
DOI : 10.1046/j.1471-4159.1999.0721243.x
Argyrophilic grain disease and Alzheimer s disease are ' distinguished by their different distribution of tau protein isoforms, Acta neuropathologica, vol.104, issue.4, pp.425-434, 2002. ,
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration, Acta Neuropathologica, vol.51, issue.Suppl 1, pp.5-22, 2007. ,
DOI : 10.1007/s00401-007-0237-2
Differentiating the Dementias. Revisiting Synucleinopathies and Tauopathies, Current Alzheimer Research, vol.5, issue.1, pp.52-60, 2008. ,
DOI : 10.2174/156720508783884657
Differentiation of geriatric major depression from Alzheimer s disease with CSF tau protein phosphorylated at threonine 231 ' . The American journal of psychiatry, pp.376-379, 2003. ,
Cerebrospinal fluid protein biomarkers for Alzheimer???s disease, NeuroRX, vol.12, issue.Suppl 179, pp.213-225, 2004. ,
DOI : 10.1602/neurorx.1.2.213
CSF markers for pathogenic processes in Alzheimer s disease: diagnostic implications and use in clinical neurochemistry ' . Brain research bulletin, pp.235-242, 2003. ,
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values, Clinical chemistry, vol.47, issue.10, pp.1776-1781, 2001. ,
Cerebrospinal Fluid Tau and ??-Amyloid, Archives of Neurology, vol.60, issue.12, pp.1696-1702, 2003. ,
DOI : 10.1001/archneur.60.12.1696
CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease, Neurology, vol.67, issue.4, pp.637-643, 2006. ,
DOI : 10.1212/01.wnl.0000230159.67128.00
Raised CSF phospho-tau concentrations in variant Creutzfeldt-Jakob disease: diagnostic and pathological implications, Journal of Neurology, Neurosurgery & Psychiatry, vol.77, issue.1, pp.89-91, 2006. ,
DOI : 10.1136/jnnp.2005.065755
Cerebrospinal fluid levels of markers of brain parenchymal damage in Vietnamese adults with severe malaria, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol.99, issue.8, pp.610-617, 2005. ,
DOI : 10.1016/j.trstmh.2004.11.017
Elevated cerebrospinal fluid tau protein levels in Wernicke s ' encephalopathy . Alcoholism, clinical and experimental research, pp.1091-1095, 2008. ,
Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients, European Journal of Paediatric Neurology, vol.12, issue.4, pp.334-341, 2008. ,
DOI : 10.1016/j.ejpn.2007.09.007
CSF biomarkers in frontotemporal lobar degeneration with known pathology, Neurology, vol.70, issue.Issue 19, Part 2, pp.1827-1835, 2008. ,
DOI : 10.1212/01.wnl.0000311445.21321.fc
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease, Annals of Neurology, vol.160, issue.5, pp.721-729, 2005. ,
DOI : 10.1002/ana.20477
CSF tau and A??42 are not useful in the diagnosis of frontotemporal lobar degeneration, Neurology, vol.62, issue.9, p.1649, 2004. ,
DOI : 10.1212/01.WNL.0000123014.03499.A7
Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies . Dementia and geriatric cognitive disorders, pp.164-170, 2005. ,
CSF diagnosis of Alzheimer???s disease and dementia with Lewy bodies, Journal of Neural Transmission, vol.313, issue.11, pp.1771-1778, 2006. ,
DOI : 10.1007/s00702-006-0537-z
Decreased CSF amyloid ??42 and normal tau levels in dementia with Lewy bodies, Neurology, vol.56, issue.4, p.576, 2001. ,
DOI : 10.1212/WNL.56.4.576
Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson s disease dementia ' . Dementia and geriatric cognitive disorders, pp.200-208, 2006. ,
Pattern of Tau forms in CSF is altered in progressive supranuclear palsy, Neurobiology of Aging, vol.30, issue.1, 2007. ,
DOI : 10.1016/j.neurobiolaging.2007.05.009
Axonal damage markers in cerebrospinal fluid are increased in ALS, Neurology, vol.66, issue.6, pp.852-856, 2006. ,
DOI : 10.1212/01.wnl.0000203120.85850.54
Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis, Acta Neurologica Scandinavica, vol.47, issue.5, pp.114-117, 2005. ,
DOI : 10.1016/S0896-6273(00)81127-7
Cerebrospinal fluid markers in differential diagnosis of Alzheimer s disease and vascular dementia, Collegium antropologicum, vol.32, pp.31-36, 2008. ,
Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis, Neuroscience Letters, vol.436, issue.1, pp.72-76, 2008. ,
DOI : 10.1016/j.neulet.2008.02.064
Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis, Multiple Sclerosis, vol.11, issue.3, pp.261-265, 2005. ,
DOI : 10.1191/1352458505ms1159oa
CSF biomarkers for Alzheimer s disease: use in early diagnosis and evaluation of drug treatment ' . Expert review of molecular diagnostics, pp.661-672, 2005. ,
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study . Archives of general psychiatry, pp.95-102, 2004. ,
Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt???Jakob disease from other dementias, Molecular Psychiatry, vol.8, issue.3, pp.343-347, 2003. ,
DOI : 10.1038/sj.mp.4001220
Decreased CSF-beta-amyloid 42 in Alzheimer s disease ' and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms . Dementia and geriatric cognitive disorders, pp.112-118, 2002. ,
Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231, Archives of Neurology, vol.59, issue.8, pp.1267-1272, 2002. ,
DOI : 10.1001/archneur.59.8.1267
Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer s disease and dementia with Lewy bodies, Clin Chem Lab Med, vol.44, issue.12, pp.1472-1480, 2006. ,
Cerebrospinal fluid tau levels in frontotemporal dementia, Annals of Neurology, vol.51, issue.4, pp.656-657, 2005. ,
DOI : 10.1002/ana.20642
Neurochemical diagnosis of Alzheimer???s dementia by CSF A??42, A??42/A??40 ratio and total tau, Neurobiology of Aging, vol.25, issue.3, pp.273-281, 2004. ,
DOI : 10.1016/S0197-4580(03)00086-1
Stability of CSF beta-amyloid(1-42) and tau levels by APOE genotype in Alzheimer patients . Dementia and geriatric cognitive disorders, pp.48-53, 2006. ,
Towards compendia of negative genetic association studies: an example for Alzheimer disease, Human Genetics, vol.8, issue.Database issue, pp.29-37, 2006. ,
DOI : 10.1007/s00439-005-0078-9
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition, Proceedings of the National Academy of Sciences, vol.105, issue.23, pp.8050-8054, 2008. ,
DOI : 10.1073/pnas.0801227105
Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer s disease ' . Molecular psychiatry, pp.510-517, 2007. ,
Association study of three polymorphisms of kinesin light-chain 1 gene with Alzheimer s disease ' . Neuroscience letters, pp.290-292, 2004. ,
Kinesin gene variability may affect tau phosphorylation in early Alzheimer s disease ', International journal of molecular medicine, vol.20, issue.2, pp.233-239, 2007. ,
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS???ADRDA criteria, The Lancet Neurology, vol.6, issue.8, pp.734-746, 2007. ,
DOI : 10.1016/S1474-4422(07)70178-3
CSF biomarkers for mild cognitive impairment and early Alzheimer's disease, Clinical Neurology and Neurosurgery, vol.107, issue.3, pp.165-173, 2005. ,
DOI : 10.1016/j.clineuro.2004.10.011
Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer s disease in patients with mild cognitive impairment, Acta Neurol Scand, vol.179, pp.47-51, 2003. ,
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI, Neurology, vol.69, issue.24, pp.2205-2212, 2007. ,
DOI : 10.1212/01.wnl.0000286944.22262.ff
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects, Neurology, vol.59, issue.4, pp.627-629, 2002. ,
DOI : 10.1212/WNL.59.4.627
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment, Neurobiology of Aging, vol.27, issue.3, pp.394-401, 2006. ,
DOI : 10.1016/j.neurobiolaging.2005.07.003
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study, The Lancet Neurology, vol.5, issue.3, pp.228-234, 2006. ,
DOI : 10.1016/S1474-4422(06)70355-6
CSF A??42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment, Neurology, vol.64, issue.7, pp.1294-1297, 2005. ,
DOI : 10.1212/01.WNL.0000156914.16988.56
CSF A??42, Tau and phosphorylated Tau, APOE ??4 allele and MCI type in progressive MCI, Neurobiology of Aging, vol.28, issue.4, pp.507-514, 2007. ,
DOI : 10.1016/j.neurobiolaging.2006.02.001
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment, Neurobiology of Aging, vol.30, issue.5, 2007. ,
DOI : 10.1016/j.neurobiolaging.2007.08.010
Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment, The Lancet Neurology, vol.2, issue.1, pp.15-21, 2003. ,
DOI : 10.1016/S1474-4422(03)00262-X
Biochemical markers in persons with preclinical familial Alzheimer disease, Neurology, vol.71, issue.2, 2008. ,
DOI : 10.1212/01.wnl.0000303973.71803.81
Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis, Neuroscience Letters, vol.363, issue.1, pp.14-17, 2004. ,
DOI : 10.1016/j.neulet.2004.03.039
CSF tau protein: A new prognostic marker for Guillain-Barre syndrome, Neurology, vol.67, issue.8, pp.1470-1472, 2006. ,
DOI : 10.1212/01.wnl.0000240119.29939.c7
Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury, Neurology, vol.67, issue.9, pp.1600-1604, 2006. ,
DOI : 10.1212/01.wnl.0000242732.06714.0f
Intra-Individual Stability of CSF Biomarkers for Alzheimer's Disease over Two Years, Journal of Alzheimer's Disease, vol.12, issue.3, pp.255-260, 2007. ,
DOI : 10.3233/JAD-2007-12307
CSF markers for incipient Alzheimer's disease, The Lancet Neurology, vol.2, issue.10, pp.605-613, 2003. ,
DOI : 10.1016/S1474-4422(03)00530-1
Core biological marker candidates of Alzheimer?s disease ? perspectives for diagnosis, prediction of outcome and reflection of biological activity, Journal of Neural Transmission, vol.111, issue.3, pp.247-272, 2004. ,
DOI : 10.1007/s00702-003-0065-z
Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia, The World Journal of Biological Psychiatry, vol.70, issue.2, pp.69-84, 2005. ,
DOI : 10.1080/01688638608405173
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia, Neurobiology of Aging, vol.29, issue.8, pp.1143-1159, 2008. ,
DOI : 10.1016/j.neurobiolaging.2007.02.016
Longitudinal changes of CSF biomarkers in memory clinic patients, Neurology, vol.69, issue.10, pp.1006-1011, 2007. ,
DOI : 10.1212/01.wnl.0000271375.37131.04
The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer s disease, Neurobiology of aging, 2008. ,
Cerebrospinal fluid biomarkers in Creutzfeldt???Jakob disease, Clinical Neurology and Neurosurgery, vol.107, issue.5, pp.355-360, 2005. ,
DOI : 10.1016/j.clineuro.2004.12.002
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework *, Clin Pharmacol Ther, vol.69, pp.89-95, 2001. ,
Microtubule-associated protein tau: A marker of paclitaxel sensitivity in breast cancer, Proceedings of the National Academy of Sciences, vol.102, issue.23, pp.8315-8320, 2005. ,
DOI : 10.1073/pnas.0408974102
Retarded Axonal Transport of R406W Mutant Tau in Transgenic Mice with a Neurodegenerative Tauopathy, Journal of Neuroscience, vol.24, issue.19, pp.4657-4667, 2004. ,
DOI : 10.1523/JNEUROSCI.0797-04.2004
Quantification and localization of kainic acid-induced neurotoxicity employing a new biomarker of cell death: cleaved microtubule-associated protein-tau (c-tau), Neuroscience, vol.121, issue.2, pp.399-409, 2003. ,
DOI : 10.1016/S0306-4522(03)00459-7
Characterization of Tau in Cerebrospinal Fluid Using Mass Spectrometry, Journal of Proteome Research, vol.7, issue.5, pp.2114-2120, 2008. ,
DOI : 10.1021/pr7008669
Detection of Alzheimer's tau protein using localised surface plasmon resonance-based immunochip, Talanta, vol.74, issue.4, pp.1038-1042, 2008. ,
DOI : 10.1016/j.talanta.2007.06.009
Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study, Nature Biotechnology, vol.14, issue.3, pp.333-338, 2006. ,
DOI : 10.1038/nbt1183
Serum Tau Protein Level as a Marker of Axonal Damage in Acute Ischemic Stroke, European Neurology, vol.47, issue.1, pp.45-51, 2002. ,
DOI : 10.1159/000047946
Neuron-specific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke, Clinical Neurology and Neurosurgery, vol.108, issue.6, pp.558-563, 2006. ,
DOI : 10.1016/j.clineuro.2005.12.006
Serum cleaved tau protein levels and clinical outcome in adult patients with closed head injury . Annals of emergency medicine, pp.254-257, 2002. ,
C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome, Brain Research, vol.947, issue.1, pp.131-139, 2002. ,
DOI : 10.1016/S0006-8993(02)02920-7
Discordant temporal patterns of S100 ?? and cleaved tau protein elevation after head injury: a pilot study, British Journal of Neurosurgery, vol.16, issue.5, pp.471-476, 2002. ,
DOI : 10.1080/0268869021000030285
Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer s ' disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay . The American journal of pathology, pp.1269-1278, 2002. ,
Longitudinal study of cerebrospinal fluid levels of tau, A?1-40, and A?1-42(43) in Alzheimer's disease: A study in Japan, Annals of Neurology, vol.37, issue.1, pp.17-26, 1998. ,
DOI : 10.1002/ana.410440108
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample, Neurology, vol.53, issue.7, pp.1488-1494, 1999. ,
DOI : 10.1212/WNL.53.7.1488
Longitudinal stability of CSF tau levels in Alzheimer patients, Biological Psychiatry, vol.46, issue.6, pp.750-755, 1999. ,
DOI : 10.1016/S0006-3223(99)00143-2
Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis, Journal of Neurology, vol.55, issue.7, pp.901-906, 2007. ,
DOI : 10.1007/s00415-006-0472-9
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke, Neuroscience Letters, vol.297, issue.3, pp.187-190, 2001. ,
DOI : 10.1016/S0304-3940(00)01697-9
Disease- and treatment-related elevation of the neurodegenerative marker tau in children with hematological malignancies, Leukemia, vol.14, issue.12, pp.2076-2084, 2000. ,
DOI : 10.1038/sj.leu.2401934
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors, Neurological Sciences, vol.23, issue.0, pp.95-96, 2002. ,
DOI : 10.1007/s100720200086
Reduction of phosphorylated tau during memantine treatment of Alzheimer s disease ' . Dementia and geriatric cognitive disorders, pp.247-252, 2007. ,
Clinical effects of A?? immunization (AN1792) in patients with AD in an interrupted trial, Neurology, vol.64, issue.9, pp.1553-1562, 2005. ,
DOI : 10.1212/01.WNL.0000159740.16984.3C
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid, Journal of Alzheimer's Disease, vol.10, issue.4, pp.399-406, 2006. ,
DOI : 10.3233/JAD-2006-10408
Association Between Tau H2 Haplotype and Age at Onset in Frontotemporal Dementia, Archives of Neurology, vol.62, issue.9, pp.1419-1422, 2005. ,
DOI : 10.1001/archneur.62.9.1419
Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model, Proceedings of the National Academy of Sciences, vol.102, issue.1, pp.227-231, 2005. ,
DOI : 10.1073/pnas.0406361102